Overview
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
Status:
Completed
Completed
Trial end date:
2017-09-28
2017-09-28
Target enrollment:
0
0
Participant gender:
All
All
Summary
The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva® Respimat®) in patients with severe persistent asthma under the real-world use was not confirmed in clinical trials.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Boehringer IngelheimTreatments:
Tiotropium Bromide
Criteria
Inclusion criteria:- Patients diagnosed with severe persistent bronchial asthma
- Patient aged >= 15 years
- Patients who are naive to Spiriva Respimat and receive Spiriva Respimat for the first
time for treatment of bronchial asthma on top of at least ICS (Inhaled
corticosteroids) treatment.
Exclusion criteria:
- Patients who have a contraindication to Spiriva Respimat defined in the package insert
for Spiriva Respimat
- Patients who have been enrolled this study before.